LPV7

**LPV7** is an investigational multipeptide cancer vaccine developed at the University of Virginia for resected high-risk melanoma. It comprises seven synthetic long peptides, each 29–31 amino acids long, derived from the melanoma-associated antigens tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1. Each peptide includes a defined CD8-positive T-cell minimal epitope and is intended to be processed and presented by antigen-presenting cells to induce tumor-antigen-specific cellular immunity. In the MEL60 Phase I/II study, LPV7 was administered with a tetanus helper peptide and evaluated with incomplete Freund's adjuvant, polyICLC, and/or resiquimod. The vaccine was generally well tolerated and produced detectable LPV7-specific T-cell responses in a subset of participants, with immune responses generally stronger in incomplete Freund's adjuvant-containing regimens.